DUOS vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $130M strategic growth equity led by FTV Capital in October 2025, bringing total funding to $163M to expand its senior-focused AI platform across Medicare Advantage, Medicaid, and ACA markets.
About
DUOS is an AI-powered digital health platform purpose-built for senior member activation and benefits execution, helping health plans drive engagement and measurable outcomes across their populations. The platform connects older adults to untapped benefits, care resources, and social services through a personalized AI layer integrated with payer workflows. Backed by $163M in total funding including FTV Capital and Forerunner Ventures, DUOS is scaling rapidly across Medicare Advantage and Medicaid nationally.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.